Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C.
about
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosisB-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related diseaseKASL clinical practice guidelines: management of hepatitis CChronic hepatitis C virus infection: Serum biomarkers in predicting liver damageLiver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact.Non-invasive prediction of forthcoming cirrhosis-related complications.Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary studyMagnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitisNoninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.Non-invasive diagnosis of advanced fibrosis and cirrhosis.Invasive and non-invasive diagnosis of cirrhosis and portal hypertensionLiver elastography, comments on EFSUMB elastography guidelines 2013.Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study.An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis.A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosisThe role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection.Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography.Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection.Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis.The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis.Methods for identifying the cost-effective case definition cut-off for sequential monitoring tests: an extension of Phelps and Mushlin.Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients.Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver BiopsyMultiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established BiomarkersDiagnostic Accuracy of the Enhanced Liver Fibrosis (ELF®) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 YearsBiomarkers in liver disease: emerging methods and potential applicationsAssociation of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score.Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV.The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters.Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C.Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian childrenNon-invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence.Treatment decisions and contemporary versus pending treatments for hepatitis C.Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis.Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease.Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.
P2860
Q21261905-E8226AB5-106E-4445-8E85-372C9CEF448CQ24658641-6BB4BE71-D5AF-4743-85EF-96B8BB41D391Q26752471-98290E08-CD01-4728-AEC7-C5956A7DCF88Q26773289-EC9E8608-3FA4-446C-803B-215D7F3AA89EQ26777511-4B78FD49-5267-4692-9B92-B76EB24DE007Q27000645-36821639-9AC7-4962-A9DB-D5DA03890323Q28082686-CFDEE6B1-5AF0-4910-8479-C91454D1E3E0Q28084035-9C103D4B-D6CA-4661-9396-12C2E014CFD2Q28727978-08063B60-E147-4CE1-98B5-C1B27564D823Q30362976-DF89AD24-4A3F-4AA8-8153-A6E9BF0C5CD3Q30397191-94E2416C-C936-43CB-9811-CDBD94FCFB38Q30423320-E7581EAB-9A04-400E-80D7-053BA041629DQ30439743-0C7C25E4-715C-4847-AB08-A9D868080B59Q30448132-89E74C17-DF88-44F6-A2FE-DF51AEDF19E6Q30449245-20730E97-4E67-4383-B60E-79D08BA2FCE9Q30453975-86F63E07-57A1-4A05-9681-203E8A2CD6F7Q30853941-4B999CE0-0C4A-41CF-A8A2-AD6AFE724124Q31157282-0EEBA06B-3EAF-45D3-A5CB-47D4BE73C4D9Q33999294-6EFF5839-E849-411A-B21B-11945BE6BB3EQ34359330-9B86C298-F9A7-4BED-93AE-977E946CCFE4Q34532528-4D5E0575-E24D-4A11-ABFD-ABDB99FEFD84Q34981143-EFA48356-6068-4922-AB34-A99515C1969EQ35109287-C9ACF748-041A-459F-9056-7CE8A19D7A9CQ35149314-CD9D94EF-6F81-40B4-B960-2855C82A2E4CQ35529346-067D212E-6550-4DA4-A570-E8039841018DQ35787865-7FED55A3-F331-45EB-872C-B39BAB32F44CQ35791614-1A8623AC-9533-4FBC-8FE6-BCF2E064DDACQ36197398-4168AF38-3636-44C8-8E04-57002AAF2FCBQ36226755-660C06BF-54B2-412F-AD11-A782844E5140Q36413685-F85366E4-DF0D-4D9F-ADAD-A4AB6DCD1CF4Q36654566-9C4E3BD2-10FF-4969-A7D9-64DDB7464A50Q36715064-6730400F-DBF8-4888-B9A3-A4A870714F1EQ36788997-5BFD6A9A-D9FC-4C25-A232-5BF39028AA1DQ37627015-15F0E8F2-0075-46A0-9E07-A6CD3A624EE2Q37675175-F6DD4605-AE18-4026-94C0-31720DA07DDCQ37868672-63D016A6-2283-4FA2-8FFC-AE6E0F9CDC6FQ38135774-22051B5C-D1F1-4D45-A513-4FD70DD5EE8BQ38175465-BA2A4A32-1665-4918-8301-2ACEC75093B1Q38204104-70F9CFCA-D5D2-4D8E-BD34-3AFC6B492AB8Q38595151-7B22F1D9-7146-47C3-8679-69B7395C6409
P2860
Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Enhanced Liver Fibrosis (ELF) ...... ents with chronic hepatitis C.
@en
Enhanced Liver Fibrosis
@nl
type
label
Enhanced Liver Fibrosis (ELF) ...... ents with chronic hepatitis C.
@en
Enhanced Liver Fibrosis
@nl
prefLabel
Enhanced Liver Fibrosis (ELF) ...... ents with chronic hepatitis C.
@en
Enhanced Liver Fibrosis
@nl
P2093
P50
P1476
Enhanced Liver Fibrosis (ELF) ...... ients with chronic hepatitis C
@en
P2093
M Wheatley
P Roderick
P2860
P356
10.1111/J.1365-2893.2009.01263.X
P577
2011-01-01T00:00:00Z